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Abstract
Background: Grand-glass nodule for CT image has thought to be less aggressive tumor in lung cancer. Echinoderm
microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)-positive lung cancer presenting with
Ground-glass nodules (GGNs) is relatively rare, and few such cases have been reported.
Case presentation: An asymptomatic 56-year-old woman exhibited a 1.1-cm GGN in the lower lobe of the left lung
on computed tomography during a medical checkup. Positron emission tomography showed no difference in uptake
by the nodule compared with other organs. We elected to perform surgery because the nodule included a solid
component and had grown only slightly during the last 2 years according to thin-section computed tomography.
Partial resection of the lower left lung was performed by video-assisted thoracic surgery. Pathological examination
revealed mucus-producing high columnar epithelium forming an irregular tubular-acinar-like structure partly replacing
the alveolar epithelium on hematoxylin and eosin staining. More than 50 % of the tumor demonstrated a lepidic
growth pattern. The tumor was negative for epidermal growth factor receptor mutation but positive for the EML4-ALK
fusion oncogene according to fluorescence in situ hybridization.
Conclusions: We herein report a case of EML4-ALK-positive lung cancer presenting with a GGN along with a review of
the relevant literature, including histopathological findings and imaging features. We consider that EML4-ALK-positive
lung cancer is often highly progressive and that careful follow-up is therefore essential in these patients.
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Background
Almost all grand-glass nodules for computed tomography
(CT) image have thought to be less aggressive tumor in
lung cancer. However, we find that there are a few GGN
that would potentially be a progressive type. Here, we
show a case of lung cancer with EML4-ALK positive that
shows GGN for CT with potentially aggressive.
Case presentation
An asymptomatic 56-year-old woman with no smoking
history exhibited a 1.1-cm ground-glass nodule (GGN)
in the lower lobe of the left lung on CT during a medical
checkup (Fig. 1a). Positron emission tomography showed
no difference in uptake by the nodule compared with
other organs (Fig. 2). All tumor markers were within the
normal range. Over 2 years, the size of the nodule had
grown from 0.9 to 1.1 cm according to thin-section CT
(Fig. 1b); thus, the patient was clinically suspected of
having lung cancer. Transbronchial lung biopsy was not
performed before surgery because the nodule was small
and peripherally located. We elected to perform surgery
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for both diagnosis and treatment. Partial resection of
the lower left lung was performed by video-assisted
thoracic surgery. The tumor with a slight change in the
visceral pleura was confirmed macroscopically. We got
a judgement of a not invasive tumor by intraoperative
pathological diagnosis; thus, lymph node excision
has not been done. Finally, pathologically, the tumor
was diagnosed as an adenocarcinoma, and mucus-
producing high columnar epithelium formed an irregu-
lar tubular-acinar-like structure partly replacing the
alveolar epithelium on hematoxylin and eosin staining
(Fig. 3a). More than 50 % of the tumor demonstrated a
lepidic growth pattern, while the remainder showed an
invasive adenocarcinoma structure. Accordingly, the
tumor was diagnosed as type C according to the
Noguchi classification. The tumor was negative for
epidermal growth factor receptor mutation but positive
for the echinoderm microtubule-associated protein-like
4-anaplastic lymphoma kinase (EML4-ALK) fusion onco-
gene according to fluorescence in situ hybridization
(Fig. 3b). Finally, the pathological stage of lung cancer was
determined to be T1aN0M0 stage 1A. The patient was
discharged on postoperative day 5 and showed no signs of
postoperative complications or recurrence 13 months
after surgery.
Discussion
The EML4-ALK fusion oncogene is present in 3.7 to
6.8 % of patients with lung adenocarcinomas [1, 2]. Few
reports have discussed the imaging features of EML4-
ALK-positive lung cancer, although many such tumors
present as solid masses. The CT findings in patients with
EML4-ALK-positive lung cancer are shown in Table 1.
EML4-ALK-positive lung cancer presenting with GGN
is relatively rare. To the best of our knowledge, only one
previous case report of a patient with EML4-ALK-positive
a b
Fig. 1 Thin-section CT showed a GGN with a small solid component in the left lower lung. CT during a medical checkup showed a nodule.
Follow-up CT 2 years after the medical checkup showed that the nodule had grown slightly. Yellow allowheads indicate the location of tumor
Fig. 2 Positron emission tomography-CT showed no abnormal accumulation in the nodule in the left lower lung. Yellow allowheads indicate the
location of tumor
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lung cancer presenting with GGN has been published [3].
In another study that examined lesions in 104 patients
with a ≥50 % GGN component on thin-section CT,
EML4-ALK positivity was only observed in 3 % of cases,
whereas epidermal growth factor receptor (EGFR)
mutation was observed in 64 % [4]. Park et al. [5] found only
one case with a GGN component among 47 EML4-ALK-
positive lung cancer cases. Fukui et al. [1] also reported only
one case with a GGN component among 28 EML4-ALK-
positive lung cancer cases, whereas 69 of 140 cases
(49.3 %) of EML4-ALK-negative lung cancer included
GGN components. Few reports have focused on the
imaging findings of EML4-ALK-positive lung cancer.
Three of the five reports in Table 1 are proceedings only,
and reports include considered both in thin-section CT
and in not thin-section CT. Therefore, it is necessary to
consider the detailed imaging features of EML4-ALK-
positive lung cancer.
The imaging features of EML4-ALK-positive lung
cancer are often discussed in relation to their histo-
pathological findings. EML4-ALK-positive lung cancer
is common among adenocarcinomas and is associated
with an acinar-type histology and sieve-like structure
and/or signet ring cells with abundant mucin growing
in solid sheets [6]. Therefore, tumors tend to present as
solid masses on CT. In the current case, however,
mucus-producing cells eventually substituted the alveo-
lar epithelium to produce an irregular tubular-acinar-
like structure, resulting in the GGN appearance.
Clinical features of EML4-ALK-positive lung cancer in-
clude onset at a younger age and a history of no to light
smoking [6, 7]. Additionally, the EML4-ALK fusion gene
is mutually exclusive of the EGFR mutation gene [8–10].
One report showed no statistically significant difference
in tumor size or lymph node metastasis at the time
of diagnosis between EML4-ALK-positive and EML4-
ALK-negative cancers [11]. Another study showed no
statistically significant difference in overall or progression-
free survival between EML4-ALK-positive and EML4-
ALK-negative cancers [7]. The same study found that
EML4-ALK-positive lung cancer tended to be diagnosed
in more advanced stages [7]; however, the present patient
showed no difference in her clinical stage for 2 years. Fur-
ther consideration of the growth speed of EML4-ALK-
positive lung cancer is needed; for example, the tumor
doubling time may be measured. However, EML4-ALK-
positive lung cancer is often highly progressive [9], and
careful follow-up is therefore essential in these patients.
Conclusions
Almost pure GGN had been considered to be less
aggressive tumor in lung cancer. In this report, we
have shown relatively rare case with potentially aggres-
sive EML4-ALK-positive lung adenocarcinoma show-
ing almost pure GGN. We have to follow this case
more carefully than usual.
Fig. 3 Histopathological observations. a Hematoxylin and eosin staining of the tumor. Mucus-producing high columnar epithelium formed an irregular
tubular-like or acinar-like structure that replaced the alveolar epithelium. b ALK immunostaining of the tumor showed an immunohistochemical iScore
of 3 (0 = no stained cells; 1 = 0–50 % stained tumor cells; 2 = 50–80 % stained tumor cells or >80 % stained tumor cells with marked variability
of staining intensity; 3 = >80 % stained tumor cells without marked variability of staining intensity)








Number of ALK+ lung cancer 36 % 28 % 28 %
With GGN 1 (2.8) 1 (3.6) 1 (20.0)
Spiculation N/A N/A 1 (20.0)
Notch N/A N/A N/A
Air bronchogram N/A N/A 4 (80.0)
Pleural indentation N/A N/A 2 (40.0)
Pleural effusion 15 (41.7) N/A N/A
Intrapulmonary metastasis N/A N/A N/A
Lymphadenopathy 31 (86.1) N/A N/A
Extended lymph node
invasion
7 (19.4) N/A N/A
Lymphangitis 3 (8.3) N/A N/A
N/A not applicable
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Consent
Written informed consent was obtained from the patient
for the publication of this case report and accompanying
images. A copy of the written consent is available for
review by the editor-in-chief of this journal.
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